Pandemic & Infectious Disease — 2026-09-22
The week's most consequential development is the FDA approval of mFlusiva, the first mRNA-based influenza vaccine for older adults, arriving just ahead of the 2026–27 respiratory season. Meanwhile, US respiratory illness activity remains very low as of mid-September CDC data, and global health experts are pressing for a shift from technical pandemic preparedness toward broader societal "readiness." The DRC Ebola outbreak remains the largest active international alert, with the WHO cautious but case counts historically high.
Pandemic & Infectious Disease — 2026-09-22
Active Outbreak Tracker
Note: The WHO Disease Outbreak News page could not be fully read this cycle (page content was not extractable), so official WHO confirmations below are limited. Reported details reflect the most recent available updates; some may predate today by a few days.
Ebola (Bundibugyo Virus) — Democratic Republic of the Congo
- Status: Ongoing outbreak; the second-largest Ebola outbreak on record, with overall case counts remaining high.
- Key Development: The WHO has expressed cautious optimism about control efforts, but case numbers remain elevated. CDC's situation summary tracks the outbreak affecting both DRC and Uganda.
- Response: WHO and DRC authorities continue outbreak control operations; CDC continues monitoring via its Ebola situation summary page.
Respiratory Illness (COVID-19, Influenza, RSV) — United States
- Status: Very low. As of September 18, 2026, CDC reports the amount of acute respiratory illness causing people to seek health care is very low nationally.
- Key Development: Pertussis (whooping cough) continues to circulate at lower levels than post-pandemic peaks, though it remains very contagious and infants under 1 year are at highest risk of severe disease.
- Response: CDC maintains its respiratory data channel and Rt-based epidemic trend estimates for COVID-19 across states and hospital service areas.
Measles — Global
- Status: Multiple ongoing outbreaks worldwide; CDC maintains a tracked list of the top 10 countries with measles outbreaks.
- Key Development: CDC's global measles outbreak tracker was updated within the past week, reflecting continued international measles activity.
- Response: CDC continues global measles vaccination surveillance and reporting.
Vaccine & Treatment Pipeline
- mFlusiva (mRNA-based influenza vaccine): FDA-approved as the first mRNA-based influenza vaccine, clearing the way for a new vaccine option for older adults ahead of the 2026–2027 flu season.
- Intismeran autogene (mRNA-4157/V940) (Moderna & Merck): Late-stage trial success — combined with pembrolizumab, it significantly improved recurrence-free and distant metastasis-free survival versus pembrolizumab alone in resected stage IIB–IV melanoma.
- XFG-adapted COVID-19 vaccine (Pfizer/BioNTech): FDA-approved for the 2026–2027 season, targeting the XFG variant in line with FDA guidance to match contemporary circulating variants; shipping began immediately.
Expert Analysis
A new Lancet commentary argues the world must fundamentally rethink pandemic readiness: moving "away from traditional technical preparedness" — tabletop exercises, surveillance and lab strengthening, PPE stockpiling, and vaccine development — toward a broader goal of readiness that includes social protection, financing, legal requirements, education, labour, food systems, and environmental governance.
This reframing follows earlier Lancet analysis arguing that global health is at "a crossroads," with concerns among health professionals about the future of pandemic preparedness and decreasing trust in health authorities.
The approval of the first mRNA influenza vaccine underscores how COVID-era mRNA platforms are now maturing into mainstream respiratory-vaccine tools — a pipeline shift experts had flagged as central to 2026's infectious disease agenda.
Global Health Security
CDC's Center for Forecasting and Outbreak Analytics continues publishing Rt (epidemic trend) estimates for COVID-19 at the national, state, and hospital service area level — an operational modeling capability that now anchors routine US outbreak forecasting.
The Vaccine Integrity Project's recent release of three evidence reviews covering 299 new studies on flu, COVID, and RSV vaccines published between August 2025 and June 2026 provides systematically updated evidence foundations for current vaccine recommendations for older adults.
Current Epidemic Trends (Based on Rt) | CFA: Modeling and Forecasting | CDC
cdc.gov
cdc.gov
Ebola Outbreak: Current Situation | Ebola | CDC
Monkeypox in the United States and Around the World: Current Situation | Monkeypox | CDC
Respiratory Illnesses Data Channel | Respiratory Illnesses | CDC
Global Measles Outbreaks | Global Measles Vaccination | CDC
What to Watch Next
- The DRC Ebola outbreak trajectory — whether WHO's "cautious optimism" holds as case counts remain historically high; the outcome will test the globalfilovirus response capacity built since previous outbreaks.
- Uptake and real-world effectiveness of mFlusiva among older adults during the 2026–27 flu season — the first real-world test of an mRNA flu vaccine.
- Whether health systems adopt the Lancet's broader "readiness" framework — including social protection and financing — ahead of the next respiratory season.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
